The identification and the long-term follow-up of new patients with MKRN3 defects and CPP could be very interesting not only for the clarification of the phenotypes according with different kinds of mutations but also for establishing their risk of metabolic disorders and estrogen-dependent tumor development later in life. This evidence concerns the gene MKRN3 and Other metabolic disease.